Enovis (ENOV) Q2 Revenue Rises 7%
Enovis (NYSE:ENOV), a medical technology company focused on orthopedics and recovery products, announced results for Q2 2025 on August 7, 2025. The headline news was a clear beat on both GAAP revenue and non-GAAP adjusted earnings per share. GAAP revenue reached $564.5 million, up 7% year over year on a reported basis and $10.9 million ahead of forecasts. Non-GAAP earnings per share were $0.79, noticeably above the $0.72 consensus. The company also raised its full-year forecasts for revenue and adjusted profit, with revenue now expected to be in the range of $2.245–2.275 billion and adjusted earnings per share guidance increased to $3.05–3.20. Despite persistent GAAP net losses, the quarter saw solid commercial momentum, new product launches, and a notable performance by the Reconstructive segment.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Enovis develops and sells medical technologies, focusing on reconstructive implants and prevention and recovery solutions. About 41% of its net sales came from outside the United States in 2024, highlighting the firm’s international reach.
Source Fool.com
